{"id":"W2519510391","doi":"10.1056/nejmoa1607141","title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2016,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":6603,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; University of Toronto; St. Michael's Hospital","funders":"Servier; Novo Nordisk Fonden; Medicines Company; Novo Nordisk; Intarcia Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Mylan; MannKind Corporation; GlaxoSmithKline","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology; Liraglutide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}